Clinical Trial Update: Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa [Phase 3]

View source ↗

Summary

Open-label extension study assessing long-term safety of Zorblisa (SD-101-6.0) in Epidermolysis Bullosa; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa

Drugs mentioned

• Zorblisa (SD-101-6.0)

Snippet

Sponsor: Scioderm, Inc. | Conditions: Epidermolysis Bullosa | Phase 3 | Status: TERMINATED | Results posted: 2019-08-02